Fullintel Daily Digest

RUTGERS CANCER INSTITUTE IN THE NEWS DECEMBER 2021

Delivered by Corporate Media Relations

Service Lines

RSNA Names Bruce G. Haffty, MD, President and Appoints Others to Board

Dec 01 | Online Publication | Reach: 201 | Sentiment : Positive

Applied Radiology Online - Bruce G. Haffty, MD, associate vice chancellor, Cancer Programs, at Rutgers Biomedical and Health Sciences, was named President of the RSNA Board during the association’s annual meeting. Dr. Haffty, who also serves as professor and chairman in the Department of Radiation Oncology at Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School. Read More

Also syndicated in:

Axis Imaging News

Syndicated Reach: TM - N/A

Germline Testing: Exploring How DNA Impacts Cancer Risk and Treatment

Dec 01 | Online Publication | Reach: 1,312 | Sentiment : Neutral

OncLive - Germline testing checks an eligible person's DNA for genetic inherited mutations that could potentially increase the risk of developing cancers or other health problems. Researchers from Rutgers Cancer Institute of New Jersey and Dana-Farber Cancer Institute developed and evaluated a computational pipeline that utilizes information commonly provided in academic and commercial tumor sequencing assays to predict the origin of detected DNA alterations with the goal of helping clinicians in identifying germline alterations in patients. Read More

ROI Influencers: Real Estate 2021 — No. 1

Dec 02 | Online Publication | Reach: 11,656 | Sentiment : Neutral

ROI-NJ - The Jack & Sheryl Morris Cancer Center: A $700 million, 520,000-square-foot addition to the Rutgers Cancer Institute of New Jersey that is a freestanding, state-of-the-art cancer hospital. Read More

ROI Influencers: Real Estate 2021 — Developers (K-Z)

Dec 02 | Online Publication | Reach: 11,656 | Sentiment : Neutral

ROI-NJ - One of the top developers, business leaders and philanthropists has remained active on a number of projects during the pandemic. The recent groundbreaking of the $750 million Jack & Sheryl Morris Cancer Center, a 12-story, 510,000-square-foot facility in New Brunswick, represents a major expansion of the Rutgers Cancer Institute, which can build a world-class cancer center here and attract people from around the world. Read More

Novel PTCH1 and Concurrent TP53 Mutations in Four Patients With Numerous Non-Syndromic Basal Cell Carcinomas: The Paradigm of Oncogenic Synergy

Dec 06 | Online Publication| Bahar Dasgeb | Reach: 4,269 | Sentiment : Neutral

Physicians Weekly - There has been a significant increase in basal cell carcinoma incidence, the most common cancer in humans, and the age of presentation with the first diagnosis of BCC has decreased in past decades. Read More

Dr. Boland on Determining When To Utilize Up-Front Perioperative Chemotherapy in CRC

Dec 06 | Online Publication| Patrick Boland | Reach: 1,312 | Sentiment : Neutral

OncLive - Patrick Boland, MD, medical oncologist, member, Gastrointestinal Oncology team, Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases. Initial considerations for up-front treatment selection in patients with CRC include assessing disease involvement in the liver, Boland says. Read More

Personal Experiences With Cancer Help Clinicians ‘Share the Journey’ With Patients

Dec 06 | Online Publication| Jennifer Byrne | Reach: 64,945 | Sentiment : Neutral

Healio - Christian S. Hinrichs, MD, is reluctant to give cancer credit for anything good. In 2015 he was chosen by the NIH as a Lasker Clinical Research Scholar, and earlier this year he was appointed chief of the section cancer immunotherapy at Rutgers Cancer Institute, New Jersey’s only NCI-designated comprehensive cancer center, where he has continued his research. “A lot of my patients struggle with uncertainty — with never knowing for sure whether the cancer will come back,” he said. “For me, it’s been a long time, so I’m relatively certain, but it’s never 100%. So, that’s something I commiserate with my patients about.” Read More

Childhood Cancer Survivors and Physical Activity

Dec 06 | Online Publication | Reach: 1,348,256 | Sentiment : Neutral

New Jersey Patch - Katie Devine, PhD, MPH, is section chief of Pediatric Population Science, Outcomes, and Disparities Research in the Division of Pediatric Hematology/Oncology at Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of Pediatrics at Rutgers Robert Wood Johnson Medical School. She shares insight on this topic. Rutgers Cancer Institute of New Jersey recently completed a study looking at the feasibility of a group-based exercise intervention paired with a wearable fitness tracker and mobile app. Read More

Also syndicated in:

HealthNewsDigest.com

Syndicated Reach: TM - 266

Living Well With Cancer-Related Fatigue

Dec 06 | Online Publication | Reach: 1,348,256 | Sentiment : Neutral

New Jersey Patch - Andrew Kass, RN, MSN, AGNP-C, AOCNP, advanced practice nurse at Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, shares more about the impact of cancer related fatigue and ways to better manage it. Unlike regular fatigue, resting with cancer related fatigue may make you more tired. Prolonged rest can lead to further loss of physical strength and endurance. Read More

Novel SERD Reduces Risk of Death by 30% in HR+ Breast Cancer

Dec 07 | Online Publication| Roxanne Nelson | Reach: 908,325 | Sentiment : Neutral

Medscape - Coral Omene, MD, PhD, a medical oncologist at Rutgers Cancer Institute of New Jersey and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, also commented on the importance of the EMERALD results. "I would think that this is practice changing," said Omene, who was also not involved in the research. The new oral SERD "demonstrates a significant advantage in progression-free survival over either fulvestrant or an aromatase Inhibitor." (Subscription Required) Read More

Study Analyzes the Contribution of AI to Cancer Patient Care and Vaccine Design

Dec 08 | Online Publication| Emily Henderson | Reach: 216,484 | Sentiment : Neutral

News-Medical.Net - In a recent viewpoint paper, investigators at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School explored how AI/ML will complement existing approaches focused on genome-protein sequence information, including identifying mutations in human tumors. We foresee that the most immediate applications of computed structure modeling will focus on point mutations detected in human tumors. Computed structure models of frequently mutated oncoproteins are already being used to help identify cancer-driver genes, enable therapeutics discovery, explain drug resistance, and inform treatment plans. Read More

Also syndicated in:

Medical Xpress, Daystech, HealthNewsDigest.com, Botswana, The Health News Express and Now You Read Me

Syndicated Reach: TM - 912,985

Piscataway Siblings Say ‘Thank You’ to Community for Holiday Toy Drive Donations

Dec 08 | Online Publication | Reach: 60,353 | Sentiment : Positive

TAPinto.net - Grateful for the support of their holiday toy drive, Piscataway siblings, Mary and Mikey Wojcik send a heartfelt thank you for the donations they’ve received so far for the young patients at Rutgers Cancer Institute of New Jersey. Read More

Exploring New Cancer Therapies That Use a Patient’s Immune System

Dec 09 | Online Publication | Reach: 1,348,256 | Sentiment : Neutral

New Jersey Patch - Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients. Christian Hinrichs, MD, chief of the Section of Cancer Immunotherapy and co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute, is the principal investigator of the study. "Adoptive cell therapy is a living treatment that harnesses the ability of immune cells to multiply and fight cancer in patients." Read More

Also syndicated in:

HealthNewsDigest.com

Syndicated Reach: TM - 201

ASH 2021 Is Packed With Practice-Changing Hematologic Cancer Data

Dec 09 | Online Publication| Gina Mauro | Reach: 1,312 | Sentiment : Neutral

OncLive - Andrew M. Evens, DO, MSc, FAC, Rutgers Cancer Institute of New Jersey: This retrospective analysis includes 785 patients with a lymphoma diagnosis and preexisting AI disease across 14 North American institutions with 694 having complete data. Investigators sought to identify associations of AI diseases with lymphoma histologic subtypes, while also evaluating prognostic and survival information. Read More

Oncolytics Biotech® Presents Positive Interim Safety Update From Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium

Dec 10 | Online Publication | Reach: 2,464,903 | Sentiment : Positive

Yahoo! Finance - The trial remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center. Mridula George, M.D., Medical Oncologist, Rutgers Cancer Institute of New Jersey, Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School, and principal investigator of the trial commented, "Checkpoint inhibitors benefit only a minority of TNBC patients due to immunosuppressive tumor microenvironments and poor PD-L1 expression." Read More

Also syndicated in:

List23 and Bloomberg

Syndicated Reach: TM - 6,647,815

Development of T-Cell Acute Lymphoblastic Leukemia

Dec 13 | Online Publication | Reach: 198 | Sentiment : Neutral

HealthNewsDigest.com - Results of the work were presented in a poster at the American Society of Hematology, during which other works are being presented by investigators from Rutgers Cancer Institute, RWJBarnabas Health and Robert Wood Johnson University Hospital. Senior author Daniel Herranz Benito, PhD, resident researcher at Rutgers Cancer Institute and assistant professor of Pharmacology at Rutgers Robert Wood Johnson Medical School shares more. Nowadays, most cases get cured by using intensive chemotherapy regimens, however, 20 to 50 percent of patients still relapse and, at this point, are refractory to current treatments and ultimately die of their disease. Read More

Also syndicated in:

News-Medical.Net

Syndicated Reach: TM - 4,084,882

Innovators in Combating Cancer

Dec 13 | Online Publication| Joe Cavaluzzi | Reach: 322 | Sentiment : Neutral

New Jersey Business Magazine - Over the years, it often seemed that the cure was worse than the disease in treating cancer. Patients feared they would emerge from treatment with permanent side effects that diminished their quality of life and ability to function. “Proton therapy is being used in treating brain tumors, head and neck cancers, thoracic, lung, gastric tumors in upper abdomen, pancreatic cancer, gynecological cancers, and other cancers and hematologic malignancies such as lymphomas,” Dr. Rahul R. Parikh, a radiation oncologist at Rutgers Cancer Institute of New Jersey and medical director of the Laurie Proton Therapy Center at Robert Wood Johnson University Hospital in New Brunswick, reports. Read More

Beyond Chemotherapy

Dec 13 | Online Publication| Liz Highleyman | Reach: 105 | Sentiment : Neutral

Cancer Health - Traditionally, cancer treatment has relied on surgery, radiation and chemotherapy—or “slash, burn and poison.” While chemotherapy is often effective, it’s not very discriminating. What’s more, efforts are underway to make chemotherapy easier to tolerate. Former Damon Runyon clinical investigator Peter Cole, MD, of Rutgers Cancer Institute of New Jersey, is working on ways to prevent chemo brain, or impaired cognition, in children with leukemia. Damon Runyon fellow Elise Jeffery, PhD, of the University of Texas Southwestern Medical Center, is investigating ways to repair bone marrow damage due to chemotherapy or radiation, while fellow Chuchu Zhang, PhD, of Harvard Medical School, is exploring the biological mechanisms underlying chemo-induced nausea. Read More

ACCO’s Distinct Advocacy Program “What About Kids?®” Leads to $25M in NEW State-Based Funding for Childhood Cancer Research

Dec 16 | Online Publication | Reach: 19,942,662 | Sentiment : Positive

Yahoo! Finance - This establishes the Pediatric Cancer Research Fund which determines how funds are utilized for childhood cancer research within the NJ Comprehensive Cancer Research Program. ACCO is proud to facilitate this $25 million for new childhood cancer research at the Rutgers Cancer Institute of NJ, Children's Hospital of Philadelphia, UPMC Children's Hospital of Pittsburgh, Penn State Children's Hospital, and Abramson at UPENN. Read More

Also syndicated in:

KPVI and Markets Insider

Syndicated Reach: TM - 940,323

Hochster Underscores Headway Made in Gastric/GEJ Cancers

Dec 16 | Online Publication | Reach: 1,312 | Sentiment : Neutral

OncLive - In today’s episode, sponsored by Daiichi Sankyo, we had the pleasure of speaking with Howard S. Hochster, MD, FACP, a distinguished professor of medicine, associate director for clinical research, and director of Gastrointestinal Oncology at Rutgers Cancer Institute, and director of oncology research at RWJBarnabas Health, to discuss some of the main implications of research over the past year on the paradigm of gastric and gastroesophageal junction cancer. Read More

Cooper Analyzes the Different Data in Transplant-Eligible Multiple Myeloma

Dec 21 | Online Publication | Reach: 181 | Sentiment : Neutral

Targeted Oncology - Dennis Cooper, MD of Rutgers Cancer Institute of New Jersey, discussed the case of a 51-year-old man with transplant-ineligible multiple myeloma during a Targeted Oncology Case-Based Roundtable event. Read More

Manahawkin Boy Honored at NJ Devils Game

Dec 21 | Online Publication| Bob Vosseller | Reach: 252 | Sentiment : Neutral

JerseyShoreOnline.com - A red carpet was set up for Lucas to walk to center ice for the special ceremonial puck drop – a faceoff between Devils Captain Nico Hischier and the Flyers’ Oskar Lindblom, a cancer survivor himself. The event hosted by the New Jersey Devils was also presented By RWJBarnabas Health with the Rutgers Cancer Institute. Funds were raised for the Cancer Center at Saint Barnabas Medical Center. The Devils also honored a special “Hero Among Us” during the Hockey Fights Cancer Night. Christian Koncewicz, a 9-year-old from Middletown, is currently undergoing treatment for leukemia at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital. Read More

Also syndicated in:

NewsBreak

Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer

Dec 21 | Online Publication| Roxanne Nelson | Reach: 908,325 | Sentiment : Neutral

Medscape - "The survival difference observed in this trial is impressive and certainly makes pyrotinib plus capecitabine a valid option for treatment," said Coral Omene, MD, PhD, a medical oncologist at Rutgers Cancer Institute of New Jersey and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, New Brunswick. Read More

Helping Patients Manage Cancer-Related Fatigue

Dec 22 | Online Publication| Lindsay Fischer | Reach: 201 | Sentiment : Neutral

Oncology Nursing News - Appropriately managing that fatigue is an important component of supportive care, because fatigue can affect whether or not patients are able to meet the everyday demands of family, friends, or work responsibilities, explained Andrew Kass, MSN, RN, AGNP-C, AOCNP, an advanced practice nurse at Rutgers Cancer Institute of New Jersey. Read More

Rutgers Cancer Institute of New Jersey Delivers Integrative Care and Collaborative Research

Dec 23 | Online Publication| Steven K. Libutti | Reach: 322 | Sentiment : Positive

New Jersey Business Magazine - Keeping patients at the center of all we do is paramount to providing exceptional cancer care. As part of our mission as the state’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health achieve this through an integrated care model in which patients have access to the state’s largest team of exceptional oncologists close to home. Read More

Exploring New Cancer Therapies That Use a Patient’s Immune System To Fight Tumors

Dec 28 | Online Publication | Reach: 1,312 | Sentiment : Positive

OncLive - Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients. Read More

Frontiers in Bone, Soft Tissue, and Hematologic Pathology

Dec 29 | Online Publication| Lanjing Zhang | Reach: N/A | Sentiment : Positive

Allen Press - Advances in tumor genetics and markers propelled updates in the most recent edition of the World Health Organization classification of soft tissue and bone tumors. Wei and Siegal thus provide an overview on the current concepts of small round cell tumors of bone and soft tissue. They focus on salient histologic features, key immunophenotypic characteristics, and recent molecular genetic advancements of these small, round cell tumors. Several emerging entities are noteworthy for their unique molecular and clinical characteristics. Read More

Examining the Development of T-Cell Acute Lymphoblastic Leukemia

Dec 31 | Online Publication| Alice Garbarini Hurley | Reach: 121,472 | Sentiment : Neutral

OncLive - Researchers from Rutgers Cancer Institute of New Jersey, the state’s only NCI-designated Comprehensive Cancer Center, examined the effects of SIRT1, an enzyme located primarily in the cell nucleus that contributes to cellular regulation on the transformation of T-cells. Results of the work are being presented in a poster at the American Society of Hematology Annual Meeting later this week, during which other works are being presented by investigators from Rutgers Cancer Institute, RWJBarnabas Health and Robert Wood Johnson University Hospital. Senior author Daniel Herranz Benito, PhD, resident researcher at Rutgers Cancer Institute and assistant professor of Pharmacology at Rutgers Robert Wood Johnson Medical School shares more. Read More

Recommended by Fullintel Analysts

You are currently subscribed as info@fullintel.com. For further assistance, please contact Customer Service at support@fullintel.com

Unsubscribe | Privacy Policy